Cargando…
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI
BACKGROUND: Neoadjuvant chemotherapy (NAC) before radical cystectomy is standard of care in patients with muscle-invasive bladder cancer (MIBC). Response assessment after NAC is important but suboptimal using CT. We assessed MRI without vs. with intravenous contrast (biparametric [BP] vs. multiparam...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644594/ https://www.ncbi.nlm.nih.gov/pubmed/37964386 http://dx.doi.org/10.1186/s40644-023-00632-0 |
_version_ | 1785147261956653056 |
---|---|
author | Woo, Sungmin Becker, Anton S. Das, Jeeban P. Ghafoor, Soleen Arita, Yuki Benfante, Nicole Gangai, Natalie Teo, Min Yuen Goh, Alvin C. Vargas, Hebert A. |
author_facet | Woo, Sungmin Becker, Anton S. Das, Jeeban P. Ghafoor, Soleen Arita, Yuki Benfante, Nicole Gangai, Natalie Teo, Min Yuen Goh, Alvin C. Vargas, Hebert A. |
author_sort | Woo, Sungmin |
collection | PubMed |
description | BACKGROUND: Neoadjuvant chemotherapy (NAC) before radical cystectomy is standard of care in patients with muscle-invasive bladder cancer (MIBC). Response assessment after NAC is important but suboptimal using CT. We assessed MRI without vs. with intravenous contrast (biparametric [BP] vs. multiparametric [MP]) for identifying residual disease on cystectomy and explored its prognostic role. METHODS: Consecutive MIBC patients that underwent NAC, MRI, and cystectomy between January 2000–November 2022 were identified. Two radiologists reviewed BP-MRI (T2 + DWI) and MP-MRI (T2 + DWI + DCE) for residual tumor. Diagnostic performances were compared using receiver operating characteristic curve analysis. Kaplan-Meier curves and Cox proportional-hazards models were used to evaluate association with disease-free survival (DFS). RESULTS: 61 patients (36 men and 25 women; median age 65 years, interquartile range 59–72) were included. After NAC, no residual disease was detected on pathology in 19 (31.1%) patients. BP-MRI was more accurate than MP-MRI for detecting residual disease after NAC: area under the curve = 0.75 (95% confidence interval (CI), 0.62–0.85) vs. 0.58 (95% CI, 0.45–0.70; p = 0.043). Sensitivity were identical (65.1%; 95% CI, 49.1–79.0) but specificity was higher in BP-MRI compared with MP-MRI for determining residual disease: 77.8% (95% CI, 52.4–93.6) vs. 38.9% (95% CI, 17.3–64.3), respectively. Positive BP-MRI and residual disease on pathology were both associated with worse DFS: hazard ratio (HR) = 4.01 (95% CI, 1.70–9.46; p = 0.002) and HR = 5.13 (95% CI, 2.66–17.13; p = 0.008), respectively. Concordance between MRI and pathology results was significantly associated with DFS. Concordant positive (MRI+/pathology+) patients showed worse DFS than concordant negative (MRI-/pathology-) patients (HR = 8.75, 95% CI, 2.02–37.82; p = 0.004) and compared to the discordant group (MRI+/pathology- or MRI-/pathology+) with HR = 3.48 (95% CI, 1.39–8.71; p = 0.014). CONCLUSION: BP-MRI was more accurate than MP-MRI for identifying residual disease after NAC. A negative BP-MRI was associated with better outcomes, providing complementary information to pathological assessment of cystectomy specimens. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00632-0. |
format | Online Article Text |
id | pubmed-10644594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106445942023-11-14 Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI Woo, Sungmin Becker, Anton S. Das, Jeeban P. Ghafoor, Soleen Arita, Yuki Benfante, Nicole Gangai, Natalie Teo, Min Yuen Goh, Alvin C. Vargas, Hebert A. Cancer Imaging Research Article BACKGROUND: Neoadjuvant chemotherapy (NAC) before radical cystectomy is standard of care in patients with muscle-invasive bladder cancer (MIBC). Response assessment after NAC is important but suboptimal using CT. We assessed MRI without vs. with intravenous contrast (biparametric [BP] vs. multiparametric [MP]) for identifying residual disease on cystectomy and explored its prognostic role. METHODS: Consecutive MIBC patients that underwent NAC, MRI, and cystectomy between January 2000–November 2022 were identified. Two radiologists reviewed BP-MRI (T2 + DWI) and MP-MRI (T2 + DWI + DCE) for residual tumor. Diagnostic performances were compared using receiver operating characteristic curve analysis. Kaplan-Meier curves and Cox proportional-hazards models were used to evaluate association with disease-free survival (DFS). RESULTS: 61 patients (36 men and 25 women; median age 65 years, interquartile range 59–72) were included. After NAC, no residual disease was detected on pathology in 19 (31.1%) patients. BP-MRI was more accurate than MP-MRI for detecting residual disease after NAC: area under the curve = 0.75 (95% confidence interval (CI), 0.62–0.85) vs. 0.58 (95% CI, 0.45–0.70; p = 0.043). Sensitivity were identical (65.1%; 95% CI, 49.1–79.0) but specificity was higher in BP-MRI compared with MP-MRI for determining residual disease: 77.8% (95% CI, 52.4–93.6) vs. 38.9% (95% CI, 17.3–64.3), respectively. Positive BP-MRI and residual disease on pathology were both associated with worse DFS: hazard ratio (HR) = 4.01 (95% CI, 1.70–9.46; p = 0.002) and HR = 5.13 (95% CI, 2.66–17.13; p = 0.008), respectively. Concordance between MRI and pathology results was significantly associated with DFS. Concordant positive (MRI+/pathology+) patients showed worse DFS than concordant negative (MRI-/pathology-) patients (HR = 8.75, 95% CI, 2.02–37.82; p = 0.004) and compared to the discordant group (MRI+/pathology- or MRI-/pathology+) with HR = 3.48 (95% CI, 1.39–8.71; p = 0.014). CONCLUSION: BP-MRI was more accurate than MP-MRI for identifying residual disease after NAC. A negative BP-MRI was associated with better outcomes, providing complementary information to pathological assessment of cystectomy specimens. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00632-0. BioMed Central 2023-11-14 /pmc/articles/PMC10644594/ /pubmed/37964386 http://dx.doi.org/10.1186/s40644-023-00632-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Woo, Sungmin Becker, Anton S. Das, Jeeban P. Ghafoor, Soleen Arita, Yuki Benfante, Nicole Gangai, Natalie Teo, Min Yuen Goh, Alvin C. Vargas, Hebert A. Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI |
title | Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI |
title_full | Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI |
title_fullStr | Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI |
title_full_unstemmed | Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI |
title_short | Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI |
title_sort | evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric mri |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644594/ https://www.ncbi.nlm.nih.gov/pubmed/37964386 http://dx.doi.org/10.1186/s40644-023-00632-0 |
work_keys_str_mv | AT woosungmin evaluatingresidualtumorafterneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancerdiagnosticperformanceandoutcomesusingbiparametricvsmultiparametricmri AT beckerantons evaluatingresidualtumorafterneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancerdiagnosticperformanceandoutcomesusingbiparametricvsmultiparametricmri AT dasjeebanp evaluatingresidualtumorafterneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancerdiagnosticperformanceandoutcomesusingbiparametricvsmultiparametricmri AT ghafoorsoleen evaluatingresidualtumorafterneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancerdiagnosticperformanceandoutcomesusingbiparametricvsmultiparametricmri AT aritayuki evaluatingresidualtumorafterneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancerdiagnosticperformanceandoutcomesusingbiparametricvsmultiparametricmri AT benfantenicole evaluatingresidualtumorafterneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancerdiagnosticperformanceandoutcomesusingbiparametricvsmultiparametricmri AT gangainatalie evaluatingresidualtumorafterneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancerdiagnosticperformanceandoutcomesusingbiparametricvsmultiparametricmri AT teominyuen evaluatingresidualtumorafterneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancerdiagnosticperformanceandoutcomesusingbiparametricvsmultiparametricmri AT gohalvinc evaluatingresidualtumorafterneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancerdiagnosticperformanceandoutcomesusingbiparametricvsmultiparametricmri AT vargasheberta evaluatingresidualtumorafterneoadjuvantchemotherapyformuscleinvasiveurothelialbladdercancerdiagnosticperformanceandoutcomesusingbiparametricvsmultiparametricmri |